Live data · NADAC + Part D CY24 · reviewed daily

Daridorexant (QUVIVIQ)

Orexin Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2022-04-07
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$36.5M in CY2024 Part D spend69K claims · 21K beneficiaries · 329 plans surveyed

Lowest NADAC
$16.70/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.70
Across all dosage forms in distribution.
Highest NADAC
$16.70
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Daridorexant used for?

Daridorexant is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Daridorexant?

No. Daridorexant is brand-only with no generic equivalents currently in market.

How much does my plan pay for Daridorexant?

Across 329 Part D plans, Daridorexant averages $16.70/unit (NADAC). Lowest available: $16.70/unit. Highest in distribution: $16.70/unit.

Is Daridorexant on the FDA shortage list?

No. Daridorexant is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.